Advertisement

Macrolide prescription in Dutch children: compliance with guidelines

  • Rosa A. M. BandellEmail author
  • Tanja Dekkers
  • Bernardus A. Semmekrot
  • Saskia N. de Wildt
  • Hanneke W. H. A. Fleuren
  • Margaretha F. Warlé-van Herwaarden
  • Peter Füssenich
  • Gerardus P. Gerrits
  • Cornelis Kramers
Original Article
  • 57 Downloads

Abstract

For reasons of antibiotic resistance and side effects, macrolides should be prescribed with care in the pediatric population. We evaluated the adherence to Dutch guidelines of macrolide prescription in children and estimated the risk of Mycoplasma pneumoniae–associated pneumonia based on Fischer’s decision tree. In this retrospective study, we included children aged 0–18 years who were treated with azithromycin or clarithromycin for pulmonary disease in four settings from general practice to hospital ward for (1) the prescriptions not in accordance with the guideline of the Dutch Association of Pediatrics and (2) the risk of M. pneumoniae in patients with community-acquired pneumonia (CAP) according to Fischer’s decision tree. The latter suggests that children older than three years with a fever lasting more than two days are at high risk for M. pneumoniae and that it is therefore justified to treat them with macrolides. In total, 189 macrolide prescriptions from 2015 until 2017 were analyzed: 139 children used macrolides for a pulmonary indication (75%); 18% (n = 25) of the prescriptions were not in accordance with Dutch guidelines. Only 9.1% of patients with CAP were classified as having a high risk of M. pneumoniae according to Fischer’s decision tree. A significant proportion of macrolide prescriptions for Dutch children with a pulmonary disease appears not to be in accordance with the guidelines. Most patients with CAP treated with a macrolide actually had a low risk of having M. pneumoniae according to Fischer’s decision tree. Both observations suggest overuse of macrolides in children.

Keywords

Microbiology Respiratory disorders Pharmacology Infectious disease medicine 

Notes

Acknowledgments

  • Dr. E.A. Croonen (Radboudumc, Department of Pediatrics, Nijmegen, The Netherlands, and Canisius Wilhelmina Hospital, Department of Pediatrics, Nijmegen, The Netherlands)

  • Mrs. J.C. Zoet-Verheul (Canisius Wilhelmina Hospital, Department of Pediatrics, Nijmegen, The Netherlands)

  • Mrs. M.W.R.G. Lennertz (Canisius Wilhelmina Hospital, Department of Outpatient Pharmacy, Nijmegen, The Netherlands)

  • Mr. J. Maliepaard (Pharmacy Nijmegen, The Netherlands)

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The regional Medical Ethical Committee Nijmegen-Arnhem waived the need for ethical approval, according to the Dutch Medical Research Involving Human Subjects Acts, as only patient chart data were collected.

Informed consent

No informed consent was required.

References

  1. 1.
    GIPdatabank Zorginstituut Nederland (2016) Aantal gebruikers naar leeftijd en geslacht voor ATC-code J01FA: Macroliden in 2015. https://www.gipdatabank.nl/databank.asp?tabel=03-lftgesl&geg=gebr&item=J01FA. Accessed 22 May 2017
  2. 2.
    GIPdatabank Zorginstituut Nederland (2016). Aantal gebruikers 2011–2015 voor ATC-subgroep J01FA: Macroliden. https://www.gipdatabank.nl/databank.asp. Accessed 22 May 2017
  3. 3.
    Kezerashvili A, Khattak H, Barsky A, Nazari R, Fisher J (2007) Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors. J Interv Card Electrophysiol 18(3):243–246CrossRefGoogle Scholar
  4. 4.
    Huang B, Wu C, Hsia C, Chen CY (2007) Azithromycin-induced torsade de pointes. Pacing Clin Electrophysiol 30(12):1579–1582CrossRefGoogle Scholar
  5. 5.
    Cheng Y, Nie X, Chen X et al (2015) The role of macrolide antibiotics in increasing cardiovascular risk. J Am Coll Cardiol 66(20):2173–2184CrossRefGoogle Scholar
  6. 6.
    Ray W, Murray K, Hall K, Arbogast P, Stein C (2012) Azithromycin and the risk of cardiovascular death. N Engl J Med 20366(17):1881–1890CrossRefGoogle Scholar
  7. 7.
    Svanström H, Pasternak B, Hviid A (2013) Use of azithromycin and death from cardiovascular causes. N Engl J Med 368(18):1704–1712CrossRefGoogle Scholar
  8. 8.
    Trac M, Mcarthur E, Jandoc R et al (2016) Macrolide antibiotics and the risk of ventricular arrhythmia in older adults. CMAJ 188(7):120–129CrossRefGoogle Scholar
  9. 9.
    Maisch N, Kochupurackal J, Sin J (2014) Azithromycin and the risk of cardiovascular complications. J Pharm Pract 27(5):496–500CrossRefGoogle Scholar
  10. 10.
    Goldstein L, Gabin A, Fawaz A et al (2015) Azithromycin is not associated with QT prolongation in hospitalized patients with community-acquired pneumonia. Pharmacoepidemiol Drug Saf 24(10):1042–1048CrossRefGoogle Scholar
  11. 11.
    Hancox J, Hasnain M, Vieweg W, Crouse E, Baranchuk A (2013) Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: a narrative review based on the study of case reports. Ther Adv Infect Dis 1(5):155–165Google Scholar
  12. 12.
    Graziani A, Hooper D, Thorner A (2016) Azithromycin, clarithromycin, and telithromycin. UpToDate. https://www.uptodate.com/contents/azithromycin-clarithromycin-and-telithromycin?source=search_result&search=azithromycin%20erythromycin&selectedTitle=1~150#H19. Accessed 18 May 2017
  13. 13.
    Lu Z, Yuan J, Li M et al (2015) Cardiac risks associated with antibiotics: azithromycin and levofloxacin. Expert Opin Drug Saf 14(2):295–303CrossRefGoogle Scholar
  14. 14.
    Espadas D, Castillo S, Moreno M, Escribano A (2016) Lack of effect of azithromycin on QT interval in children: a cohort study. Arch Dis Child 101(11):10796CrossRefGoogle Scholar
  15. 15.
    Germanakis I, Galanakis E, Parthenakis F, Vardas P, Kalmanti M (2006) Clarithromycin treatment and QT prolongation in childhood. Acta Paediatr 95(12):1694–1696CrossRefGoogle Scholar
  16. 16.
    Promphan W, Khongphatthanayothin A, Horchaiprasit K, Benjacholamas V (2003) Roxithromycin induced torsade de pointes in a patient with complex congenital heart disease and complete atrioventricular block. Pacing Clin Electrophysiol 26(6):1424–1426CrossRefGoogle Scholar
  17. 17.
    Tilelli J, Smith K, Pettignano R (2006) Life-threatening bradyarrhythmia after massive azithromycin overdose. Pharmacotherapy 26(1):147–150CrossRefGoogle Scholar
  18. 18.
    Meyer Sauteur PM, Unger WW, Nadal D, Berger C, Vink C, van Rossum AM (2016) Infection with and carriage of Mycoplasma pneumoniae in children. Front Microbiol 7(329):1–12Google Scholar
  19. 19.
    Klein J (1997) History of macrolide use in pediatrics. Pediatr Infect Dis J 16(4):427–431CrossRefGoogle Scholar
  20. 20.
    Filho LS, Pinto L, Stein R (2015) Use of macrolides in lung diseases: recent literature controversies. J Pediatr 91:52–60CrossRefGoogle Scholar
  21. 21.
    Nederlands Kenniscentrum Farmacotherapie bij Kinderen (2017) Claritromycine, kinderformularium. https://www.kinderformularium.nl/geneesmiddel/311/claritromycine. Accessed 1 June 2017
  22. 22.
    Nederlands Kenniscentrum Farmacotherapie bij Kinderen (2017) Azitromycine, kinderformularium. https://www.kinderformularium.nl/geneesmiddel/309/azitromycine. Accessed 1 June 2017
  23. 23.
    Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie (2017) Azitromycine. https://kennisbank.knmp.nl/article/Informatorium_Medicamentorum/S2424.html. Accessed 1 June 2017
  24. 24.
    Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie (2016) Claritromycine. https://kennisbank.knmp.nl/article/Informatorium_Medicamentorum/S2347.html. Accessed 1 June 2017
  25. 25.
    Southern KW, Barker PM, Solis-Moya A, Patel L (2012) Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 11Google Scholar
  26. 26.
    Wong E, Porter J, Edwards M, Johnston S (2014) The role of macrolides in asthma: current evidence and future directions. Lancet Respir Med 2(8):657–670CrossRefGoogle Scholar
  27. 27.
    Lin S, Lee W, Liang Y, Yan D, Cheng P, Kuo M (2011) Azithromycin inhibits IL-5 production of T helper type 2 cells from asthmatic children. Int Arch Allergy Immunol 156:179–186CrossRefGoogle Scholar
  28. 28.
    Stokholm J, Chawes B, Vissing N et al (2016) Azithromycin for episodes with asthma-like symptoms in young children aged 1-3 years: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 4:19–26CrossRefGoogle Scholar
  29. 29.
    Gardiner SJ, Gavranich JB, Chang AB (2015) Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst Rev 1Google Scholar
  30. 30.
    Raissy H, Blake K (2016) Macrolides for acute wheezing episodes in preschool children. Pediatr Allergy Immunol Pulmonol 29(2):100–103CrossRefGoogle Scholar
  31. 31.
    Bacharier L, Guilbert T, Mauger D et al (2015) Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial. JAMA 314(19):2034–2044CrossRefGoogle Scholar
  32. 32.
    Fleming-Dutra K, Friedman C, Hicks L (2016) Comments and respons: early azithromycin treatment to prevent severe lower respiratory tract illnesses in children. JAMA 315(19):2121–2122CrossRefGoogle Scholar
  33. 33.
    Nederlands Huisartsen Genootschap (2017). Richtlijnen en Praktijk. https://www.nhg.org/richtlijnen-praktijk. Accessed 15 June 2017
  34. 34.
    Nederlandse Vereniging voor Kindergeneeskunde (2017). Richtlijnen overzicht. https://www.nvk.nl/Kwaliteit/Richtlijnenoverzicht.aspx. Accessed 15 June 2017
  35. 35.
    Terheggen-Lagro S, Vreede ID, Tuut M, et al (2015) NVK-richtlijn (guideline of the Dutch Association of Pediatrics). Richtlijn diagnostiek en behandeling van ongecompliceerde pneumonie bij kinderen in de tweede en derde lijn (guideline diagnostics and treatment of uncomplicated pneumonia in children in the second- and third-line). http://www.kindergeneeskunde-mca.nl/images/stories/medische_protocollen/pneumonierichtlijn2015.pdf. Accessed 15 June 2017
  36. 36.
    Wang K, Gill P, Perera R, Thomson A, Mant D, Harnden A (2012) Clinical symptoms and signs for the diagnosis of Mycoplasma pneumoniae in children and adolescents with community-acquired pneumonia. Cochrane Database Syst Rev 10Google Scholar
  37. 37.
    Fischer J, Steiner F, Zucol F et al (2002) Use of simple heuristics to target macrolide prescription in children with community-acquired pneumonia. Arch Pediatr Adolesc Med 156:1005–1008CrossRefGoogle Scholar
  38. 38.
    Katsikopoulos K, Pachur T, Machery E, Wallin A (2008) From meehl to fast and frugal heuristics (and back): new insights into how to bridge the clinical-actuarial divide. Theory Psychol 18(4):443–464CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Rosa A. M. Bandell
    • 1
    • 2
    Email author
  • Tanja Dekkers
    • 3
  • Bernardus A. Semmekrot
    • 1
  • Saskia N. de Wildt
    • 4
    • 5
  • Hanneke W. H. A. Fleuren
    • 2
  • Margaretha F. Warlé-van Herwaarden
    • 6
  • Peter Füssenich
    • 7
  • Gerardus P. Gerrits
    • 1
  • Cornelis Kramers
    • 2
    • 4
  1. 1.Department of PediatricsCanisius Wilhelmina HospitalNijmegenThe Netherlands
  2. 2.Department of Clinical PharmacyCanisius Wilhelmina HospitalNijmegenThe Netherlands
  3. 3.Department of Internal MedicineRadboudumcNijmegenThe Netherlands
  4. 4.Department of Pharmacology-ToxicologyRadboudumcNijmegenThe Netherlands
  5. 5.Intensive Care and Department of Pediatric SurgeryErasmus MC SophiaRotterdamThe Netherlands
  6. 6.Community PharmacyGroesbeekThe Netherlands
  7. 7.General PracticeGroesbeekThe Netherlands

Personalised recommendations